Literature DB >> 26870234

Costimulation with anti-cluster of differentiation 3 and anti-cluster of differentiation 28 reduces the activity of mucin 1-stimulated human mononuclear cells.

Stephen E Wright1, Kathleen A Rewers-Felkins2, Imelda Quinlin2, Fatema Zohra2, Jewel Ahmed2.   

Abstract

Cytotoxic T-lymphocyte activation and extension of the cell life span is necessary in order to enable immunotherapy to perform effectively against cancer. In the present study, mucin 1 (MUC1)-stimulated human mononuclear cells (M1SHMCs) were costimulated with bead-attached monoclonal antibodies specific for cluster of differentiation (CD)3 and CD28 receptors. The study was undertaken to determine whether costimulation was capable of enhancing the killing of cancer cells in vitro and of protecting non-obese diabetic severe combined immunodeficient mice from tumor development. Lysis of MCF-7 tumor cells by M1SHMCs was reduced following costimulation with anti-CD3 and anti-CD28. Furthermore, costimulation with anti-CD3 and anti-CD28 eliminated the protective effects of M1SHMCs on MCF-7 breast cancer cell growth in the non-obese diabetic severe combined immunodeficient mice. The present study suggested that costimulation with anti-CD3 and anti-CD28 is not advisable following antigen activation of lymphocytes under the conditions used here. Using a lower anti-CD3/CD28 bead to T-cell ratio may prevent immune suppression, however, further studies are required to support this hypothesis.

Entities:  

Keywords:  anti-cluster of differentiation 28; anti-cluster of differentiation 3; mononuclear cells; mucin 1

Year:  2015        PMID: 26870234      PMCID: PMC4732541          DOI: 10.3892/ol.2015.3840

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

1.  Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies.

Authors:  Dale Kalamasz; S A Long; Ruth Taniguchi; Jane H Buckner; Ronald J Berenson; Mark Bonyhadi
Journal:  J Immunother       Date:  2004 Sep-Oct       Impact factor: 4.456

2.  Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site.

Authors:  S E Wright; L Kilinski; S Talib; K E Lowe; J S Burnside; J Y Wu; N Dolby; K E Dombrowski; J S Lebkowski; R Philip
Journal:  J Immunother       Date:  2000-01       Impact factor: 4.456

3.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.

Authors:  L H Boise; A J Minn; P J Noel; C H June; M A Accavitti; T Lindsten; C B Thompson
Journal:  Immunity       Date:  1995-07       Impact factor: 31.745

4.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.

Authors:  S R Riddell; P D Greenberg
Journal:  J Immunol Methods       Date:  1990-04-17       Impact factor: 2.303

5.  Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells.

Authors:  Stephen E Wright; Kathleen A Rewers-Felkins; Imelda S Quinlin; Paul W Eldridge; Paul E Zorsky; Panpit P Klug; Catherine A Phillips; Ramila Philip
Journal:  Int J Mol Med       Date:  2002-04       Impact factor: 4.101

6.  Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD.

Authors:  Annette Künkele; Adam J Johnson; Lisa S Rolczynski; Cindy A Chang; Virginia Hoglund; Karen S Kelly-Spratt; Michael C Jensen
Journal:  Cancer Immunol Res       Date:  2015-01-09       Impact factor: 11.151

7.  Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Authors:  Matthew J Frigault; Jihyun Lee; Maria Ciocca Basil; Carmine Carpenito; Shinichiro Motohashi; John Scholler; Omkar U Kawalekar; Sonia Guedan; Shannon E McGettigan; Avery D Posey; Sonny Ang; Laurence J N Cooper; Jesse M Platt; F Brad Johnson; Chrystal M Paulos; Yangbing Zhao; Michael Kalos; Michael C Milone; Carl H June
Journal:  Cancer Immunol Res       Date:  2015-01-19       Impact factor: 11.151

8.  Generation of MUC1-stimulated mononuclear cells using optimized conditions.

Authors:  S E Wright; R Khaznadar; Z Wang; I S Quinlin; K A Rewers-Felkins; C A Phillips; S Patel
Journal:  Scand J Immunol       Date:  2007-11-15       Impact factor: 3.487

Review 9.  Chimeric antigen receptor therapy for cancer.

Authors:  David M Barrett; Nathan Singh; David L Porter; Stephan A Grupp; Carl H June
Journal:  Annu Rev Med       Date:  2013-11-20       Impact factor: 13.739

10.  Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.

Authors:  Harjeet Singh; Matthew J Figliola; Margaret J Dawson; Simon Olivares; Ling Zhang; Ge Yang; Sourindra Maiti; Pallavi Manuri; Vladimir Senyukov; Bipulendu Jena; Partow Kebriaei; Richard E Champlin; Helen Huls; Laurence J N Cooper
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.